

Title: PHS 2010-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])

PA#: PA-10-050

Link: <http://grants.nih.gov/grants/guide/pa-files/PA-10-050.html>

Due Dates: April 5, 2010, August 5, 2010, December 5, 2010

Eligible Institutions: Only U.S. SBCs are eligible to submit and receive SBIR grants.

Purpose:

The SBIR program, as established by law, is intended to meet the following goals:

- stimulate technological innovation in the private sector;
- strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs;
- increase the commercial application of Federally-supported research results;
- foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns in the SBIR program; and
- improve the return on investment from Federally-funded research for economic and social benefits to the Nation.

The SBIR program is structured in three phases, the first two of which are supported using SBIR funds. The objective of Phase I is to establish the technical/scientific merit and feasibility of the proposed R/R&D efforts. The objective of Phase II is to continue the research or R&D efforts initiated in Phase I. An objective of the SBIR program is to increase private sector commercialization of innovations derived from Federal R/R&D. The objective of Phase III, where appropriate, is for the SBC to pursue with non-SBIR funds (either Federal or non-Federal) the commercialization objectives resulting from the results of the R/R&D funded in Phases I and II. In some Federal agencies, Phase III may involve follow-on, non-SBIR funded R&D, or production contracts for products or processes intended for use by the U.S. Government.

The competition for SBIR Phase I and Phase II awards satisfies the competition requirement of the Armed Services Procurement Act, the Federal Property and Administrative Services Act, and the Competition in Contracting Act. Therefore, an agency that wishes to fund an SBIR Phase III project is not required to conduct another competition in order to satisfy those statutory provisions. As a result, in conducting actions relative to a Phase III SBIR award, it is sufficient to state for purposes of a Justification and Approval pursuant to FAR 6.302-5 that the project is a SBIR Phase III award that is derived from, extends, or logically concludes efforts performed under prior SBIR funding agreements and is authorized under 10 U.S.C. 2304(b)(2) or 41 U.S.C. 253(b)(2).

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC) the Food and Drug Administration (FDA), and the Administration for Children and Families (ACF) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) Phase I, Phase II, Fast-Track (NIH only), and Phase II Competing Renewal (NIH only) grant applications.

The [PHS 2010-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, FDA, and ACF](#) represent scientific program areas that may be of interest to applicant SBCs in the development of projects that have potential for commercialization. Small business concerns that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, FDA, and ACF awarding components identified in this FOA are encouraged to submit SBIR grant applications in these areas. SBIR grant applications will also be accepted and considered in any area

within the mission of the [Components of Participating Organizations](#) listed for this FOA. In addition to the general research areas described above some NIH awarding components have identified additional, specific SBIR funding opportunities of potential interest to SBCs. See the [NIH Special Announcements for Small Business Research Opportunities](#). Applicants are not required to identify a potential awarding component prior to submission of the application. Staff within the NIH's Center for Scientific Review (CSR) office, the single receiving point for all NIH, FDA, CDC, and ACF grant applications, will assign all applications to the most appropriate Institute/Center (IC) based on their mission and the science proposed.

Budget and Period of Performance:

Phase I awards normally may not exceed \$100,000 total for a period normally not to exceed 6 months. Phase II awards normally may not exceed \$750,000 total for a period normally not to exceed 2 years. These award levels and project periods are statutory guidelines, not ceilings. Therefore, applicants are encouraged to propose a budget and project duration period that are reasonable and appropriate for completion of the research project. Phase II Competing Renewal budgets must be submitted in accordance with participating IC-specific budget limitations described in the current [SBIR/STTR Program Descriptions and Research Topics](#) of the NIH, CDC and FDA.